Medical Condition News

RSS

Encouraging early clinical results for treatment of KC with Avedro's Keraflex KXL technology

During the 5th International Congress of Corneal Cross Linking for Keratoconus in Leipzig, Germany on December 5th, Avedro presented encouraging early clinical results for treating keratoconus, a progressive disease of the cornea of the eye. The procedure, known as Keraflex® KXL, is non-incisional and reshapes the cornea without removing any tissue.

16 Dec 2009

Naurex' GLYX-13 demonstrates antidepressant-like and anxiolytic-like activity without CNS-related side effects

Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that data presented at a major medical meeting showed that its lead compound GLYX-13 demonstrated robust antidepressant-like and anxiolytic-like activity with no signs of the CNS-related side effects seen with other drugs targeting the NMDA receptor.

16 Dec 2009

Naurex commences dosing in its GLYX-13 Phase I clinical trial for treatment-resistant depression

Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that it has initiated a Phase I clinical trial of its lead compound GLYX-13 and has successfully dosed the first subjects in the study.

16 Dec 2009

Patients involved in Novelos Therapeutics' pivotal Phase III trial live longer than expected

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has published an exclusive interview with the CEO of Novelos Therapeutics, Inc., Harry S. Palmin.

16 Dec 2009

Roche's P2X3 receptor program for chronic pain licensed to Afferent Pharmaceuticals

Roche announced today it has licensed its P2X3 receptor program aimed at developing first-in-class treatments for chronic pain to Afferent Pharmaceuticals. Afferent was co-founded by Anthony Ford, Ph.D., Pappas Ventures, and Third Rock Ventures, and is focused on developing compounds that treat chronic pain by targeting a novel biological pathway.

16 Dec 2009

Studies reveal new benefits of Peptan in preventing osteoporosis

Studies Conducted at INRA-Agroparistech Laboratory Under Pr. Daniel Tome's Supervision and Published in November 2009, in the Official Journal of the International Bone and Mineral Society "Bone", Reveal new Benefits for Peptan(TM) in Osteoporosis Prevention

16 Dec 2009

Cancer Research UK's phase I trial results of CHT25 published in Clinical Cancer Research

TWO THIRDS of Hodgkin's lymphoma patients treated with an experimental radioactive cancer therapy responded well to the treatment, reveal the results of a Cancer Research UK phase I trial published in Clinical Cancer Research, today (Tuesday).

16 Dec 2009

Deaths from heart disease peak in December and January, US database reveals

'Tis the season… for a heart attack? According to Dr. Keith Churchwell, associate director of the Vanderbilt Heart and Vascular Institute at Vanderbilt University Medical Center, a US database of 53 million deaths occurring between 1973 and 2001 reveals that deaths from heart disease peak in December and January, with spikes on Christmas and New Year's Day.

16 Dec 2009

Pharmacy directors willing to cover tanezumab at lower prices

HealthLeaders-InterStudy and Fingertip Formulary find that 70 percent of surveyed pharmacy directors expect to cover Pfizer's tanezumab if it is approved for the treatment of chronic pain. Tanezumab, which is expected to be the first biologic approved for chronic pain and is administered intravenously under medical supervision, will likely be covered as a medical benefit rather than a pharmacy benefit according to surveyed pharmacy directors.

16 Dec 2009

Challenges U.S. and U.K. cancer patients face in gaining access to expensive treatments

Cancer patients in both the United States and the United Kingdom face challenges in gaining access to expensive treatments, according to research published in the December issue of The Milbank Quarterly.

16 Dec 2009

Spiritual care can improve outcomes in terminally ill cancer patients

In a new study of terminally ill cancer patients, researchers at Dana-Farber Cancer Institute found support of patients' spiritual needs by the medical team is associated with greater use of hospice, less aggressive care, and greater quality of life near death. The

16 Dec 2009

Modulating PN aggregase pathway may offer hope for Alzheimer’s disease

Proteostasis Therapeutics announced today that modulating a key Proteostasis Network (PN) pathway may offer a novel approach to Alzheimer’s disease, a finding that was published in the journal Cell by its scientific founders Andrew Dillin, Ph.D., and Jeffery Kelly, Ph.D. The publication describes how regulation of an aggregase pathway reduced the neurodegenerative effects of beta amyloid aggregates that are a hallmark of the disease.

16 Dec 2009

VA and Department of Defense clinical practice guidelines for mTBI

The current issue of the Department of Veterans Affairs (VA's) Journal of Rehabilitation Research and Development (JRRD) features 19 timely scientific articles on traumatic brain injury (TBI), based on work by VA researchers and colleagues from a variety of disciplines. The papers were commissioned for a "state of the art" conference VA held last year to advance research in this area.

16 Dec 2009

EDP Biotech develops a simple blood test for detecting early-stage colon cancer

Medical researchers with EDP Biotech Corporation (EDP) have captured national attention with their revolutionary new technology for a simple blood test to detect early-stage colon cancer.

16 Dec 2009

Englerin A possesses high toxicity for kidney cancer cells, researchers discover

Englerin A, a natural product recently discovered in an African plant, possesses high toxicity for kidney cancer cells but low toxicity for other cells. Therefore this compound is potentially qualified for further evaluation toward an application in cancer therapy.

16 Dec 2009

ThromboGenics completes enrollment in second microplasmin Phase III trial

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that it has completed the enrolment of the second Phase III trial evaluating microplasmin for the non-surgical treatment of eye disease.

16 Dec 2009

Celebrities unveil Race for Life 2010 t-shirts to raise money for Cancer Research UK

A TRIO of celebrities including choreographer, Arlene Phillips; girlfriend of Arsenal star Theo Walcott, Melanie Slade; and fashion designer Tracey Boyd, have given the classic white tee a fun twist with a splash of colour as their new collection of Race for Life 2010 t-shirts is unveiled to raise money for Cancer Research UK.

16 Dec 2009

Preclinical study of Arno Therapeutics' drug candidate AR-42 presented at ASH 2009

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology therapeutics, today announced the presentation of a poster at the annual American Society of Hematology (ASH) meeting that describes the preclinical activity of Arno’s drug candidate AR-42 against leukemia stem cells (LSCs).

16 Dec 2009

NEI study reports 66.4 percent increase in myopia in Americans

According to the American Academy of Ophthalmology, the 66.4 percent increase in myopia in Americans since the 1970s, as reported in the recent National Eye Institute (NEI) study, is significant and will impact healthcare costs as well as vision quality.

16 Dec 2009

Physicians need to utilize best practices to treat HAE patients in emergency settings

Hereditary Angioedema (HAE) is an autosomal dominant disease causing acute attacks of intense edema. These attacks can result in life-threatening complications, including asphyxiation.

16 Dec 2009

Medical Condition News

Encouraging early clinical results for treatment of KC with Avedro's Keraflex KXL technology

Naurex' GLYX-13 demonstrates antidepressant-like and anxiolytic-like activity without CNS-related side effects

Naurex commences dosing in its GLYX-13 Phase I clinical trial for treatment-resistant depression

Patients involved in Novelos Therapeutics' pivotal Phase III trial live longer than expected

Roche's P2X3 receptor program for chronic pain licensed to Afferent Pharmaceuticals

Studies reveal new benefits of Peptan in preventing osteoporosis

Cancer Research UK's phase I trial results of CHT25 published in Clinical Cancer Research

Deaths from heart disease peak in December and January, US database reveals

Pharmacy directors willing to cover tanezumab at lower prices

Challenges U.S. and U.K. cancer patients face in gaining access to expensive treatments

Spiritual care can improve outcomes in terminally ill cancer patients

Modulating PN aggregase pathway may offer hope for Alzheimer’s disease

VA and Department of Defense clinical practice guidelines for mTBI

EDP Biotech develops a simple blood test for detecting early-stage colon cancer

Englerin A possesses high toxicity for kidney cancer cells, researchers discover

ThromboGenics completes enrollment in second microplasmin Phase III trial

Celebrities unveil Race for Life 2010 t-shirts to raise money for Cancer Research UK

Preclinical study of Arno Therapeutics' drug candidate AR-42 presented at ASH 2009

NEI study reports 66.4 percent increase in myopia in Americans

Physicians need to utilize best practices to treat HAE patients in emergency settings

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News